News and Publications

이뮨온시아, ‘PD-L1 억제 면역항암제’ 2상 승인

By admin| 2020-05-22T10:34:04+00:00 2020/05/22|News and Publications|

Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)

By admin| 2020-04-27T10:15:44+00:00 2020/04/27|News and Publications|

이뮨온시아,면역항암제 후보물질 임상 계획 미국 FDA 제출

By admin| 2020-03-13T16:46:41+00:00 2020/03/13|News and Publications|

KDDF, ‘차이나 서밋’ 참여해 국내 투자 유치 도모

By admin| 2019-12-04T17:04:55+00:00 2019/12/04|News and Publications|

이뮨온시아, 면역함암제 임상1상 결과 공개

By admin| 2019-12-04T16:57:58+00:00 2019/12/04|News and Publications|

사노피 출신 대표가 이끌고, 유한이 선택한 ‘그 회사’

By admin| 2019-10-22T09:54:19+00:00 2019/10/21|News and Publications|

ImmuneOncia has been selected by the Korea Drug Development Fund to develop an immune therapy targeting a cancer-aiding protein.

By admin| 2019-09-19T11:14:00+00:00 2019/09/19|News and Publications|

Yuhan Corp and Sorrento Therapeutics announce completion of phase 1 clinical study of anti-PD-L1 antibody IMC-001

By admin| 2019-09-19T11:15:56+00:00 2019/03/20|News and Publications|

Yuhan Corp and Sorrento Therapeutics announce closing of a $40M USD Financing for joint venture ImmuneOncia to support advancement of Immuno-Oncology program

By admin| 2019-03-15T18:47:45+00:00 2019/02/18|News and Publications|

Sorrento’s and Yuhan’s joint venture, ImmuneOncia, receives approval to begin clinical trial of anti-PD-L1 monoclonal antibody in South Korea

By admin| 2019-09-19T11:17:55+00:00 2018/03/07|News and Publications|

Previous 1 2 3 4 Next